Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486577 | 0.87 | CCR2 (0.50) | LTA4HEPHX2KMT2ADRD3CHRNA4 | |
| SCHEMBL5870682 | 0.86 | OPRD1 (0.62) | OPRD1OPRM1OPRK1DRD3CHRNA4 | |
| SCHEMBL5870685 | 0.86 | OPRD1 (0.62) | OPRD1OPRM1OPRK1DRD3CHRNA4 | |
| SCHEMBL5870753 | 0.86 | OPRD1 (0.62) | OPRD1OPRM1OPRK1DRD3CHRNA4 | |
| SCHEMBL5870944 | 0.83 | OPRM1 (0.50) | LTA4HEPHX2OPRD1KMT2AOPRM1 | |
| SCHEMBL5870761 | 0.83 | OPRM1 (0.50) | LTA4HEPHX2OPRD1KMT2AOPRM1 | |
| SCHEMBL5870894 | 0.82 | OPRD1 (0.49) | OPRD1KMT2AOPRM1CHRNA4CHRM1 | |
| SCHEMBL6497878 | 0.80 | PKM (0.47) | DRD3CHRNA4KCNH2CHRNB2CCR2 | |
| SCHEMBL5870861 | 0.80 | CHRM1 (0.56) | OPRD1OPRM1OPRK1DRD3CHRNA4 | |
| SCHEMBL5870741 | 0.80 | OPRD1 (0.57) | OPRD1OPRM1OPRK1CHRNA4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946477-B2 | 3-Substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | AQUILA BRIAN M (US) | 2003-06-19 | — | — | US | disclosed |
| US-6476050-B2 | ANALGESICS; LIGANDS FOR VARIOUS CELLULAR RECEPTORS, INCLUDING OPIOID RECEPTORS, OTHER G-PROTEIN-COUPLED RECEPTORS AND ION CHANNELS | SEPRACOR, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | LTA4H 979/4885EPHX2 1187/4885OPRD1 5/4885 |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | LTA4H 979/4885EPHX2 1187/4885OPRD1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.